Hyphens Pharma Launches Winlevi® in Singapore and Malaysia, Ushering in a New Era of Acne Treatment in Southeast Asia

18 July 2025 | Friday | News

First-in-class topical androgen receptor inhibitor now available by prescription, offering patients a novel, skin-targeted solution for acne with a strong safety profile

Hyphens Pharma Pte. Ltd., a subsidiary of SGX Catalist-listed Hyphens Pharma International Limited, Singapore’s leading specialty pharmaceutical and consumer healthcare group would like to announce the launch of Winlevi® (clascoterone) cream 1% in Singapore and Malaysia – marking its first entry into Southeast Asia. Registration is underway in other Southeast Asian markets, with rollout to follow progressively.

Now available in Singapore and Malaysia via prescription through clinics and hospitals, Winlevi® is a novel topical acne treatment with a unique mechanism of action. Winlevi® is the first new class of molecule in acne treatment in over 40 years, acting through a novel mechanism of action that targets the androgen-sebum pathway directly within the skin. Its active ingredient, clascoterone, is the first commercially available topical androgen receptor inhibitor for acne, reducing sebum production and inflammation without causing systemic anti-androgen side effects. This makes it a safe choice for both male and female patients with acne.

This launch reinforces Hyphens Pharma’s strategic expansion in the dermatology space - which is one of the Company's core therapeutic focus areas which includes treatments for acne, atopic dermatitis, hyperpigmentation, and hair loss, distributed through dermatologists, paediatricians, general practitioners and major retail pharmacies across Southeast Asia.

Mr Lim See Wah (林世华), Executive Chairman and CEO of Hyphens Pharma, added: “We’re proud to be the first to introduce Winlevi® to Southeast Asia. Acne affects millions in the region, yet for decades, patients have had limited treatment options. This launch marks a significant advancement in acne care, our dermatology portfolio and partnership with Cosmo. We appreciate their trust in us to bring this transformative treatment to the region. Acne isn’t just skin-deep – it can impact psychosocial well-being. By expanding access to Winlevi®, we aim to support doctors in their practice and empower patients to manage acne with greater confidence, improving their quality of life.”

Hyphens Pharma Launches Winlevi® in Singapore and Malaysia, Ushering in a New Era of Acne Treatment in Southeast Asia

Stay Connected